Skip to main content
. 2015 Dec 4;7(3):2809–2822. doi: 10.18632/oncotarget.6465

Figure 4. Ulocuplumab (BMS-936564) antibody induces apoptosis in CLL cells independent of TP53 status.

Figure 4

A. The primary leukemia B-cells were obtained from CLL patients with or without TP53 mutation or Del(17p) [TP53mut /Del(17p)]. Normal B and T lymphocytes were obtained from healthy donors. The % SIA was measured in normal B, T cells, CLL cells, TP53mut /Del(17p) CLL cells, alone or co-cultured with stroma-NK-tert cells after treatment with 200 nM of Ulocuplumab (BMS-936564) for 48 hrs of incubation at 37°C. % SIA of Normal B and T cells was significantly less when compared to CLL-LR, CLL-HR and TP53mut /Del(17p) patients, showing that Ulocuplumab (BMS-936564) has a good therapeutic index. Ulocuplumab (BMS-936564) induced apoptosis in CLL cells regardless of TP53mut /Del(17p) mutation status, while normal B or T cells showed statistically-lower level of apoptosis. The data shows the results of samples analyzed in duplicate with the mean and its respective standard deviations. B. Representative CLL samples from each subgroup - TP53wt or TP53mut /Del(17p) and Ramos TP53 mutant were incubated for 48 hrs with the Ulocuplumab (BMS-936564) and Fludarabine (F-ara-A). Apoptosis was measured by flow cytometry.